Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma

Paul D. Harker-Murray, Richard A. Drachtman, David C. Hodgson, Allen Russell Chauvenet, Kara M. Kelly, Peter David Cole

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk-stratified, response-based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579-586.

Original languageEnglish (US)
Pages (from-to)579-586
Number of pages8
JournalPediatric Blood and Cancer
Volume61
Issue number4
DOIs
StatePublished - Apr 2014

Fingerprint

Hodgkin Disease
Hematopoietic Stem Cell Transplantation
Pediatrics
Drug Therapy
Radiotherapy
Therapeutics
Recurrence
Survival
Neoplasms

Keywords

  • Chemotherapy
  • Hematopoietic cell transplant
  • Hodgkin lymphoma
  • Pediatric oncology
  • Relapse

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Harker-Murray, P. D., Drachtman, R. A., Hodgson, D. C., Chauvenet, A. R., Kelly, K. M., & Cole, P. D. (2014). Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatric Blood and Cancer, 61(4), 579-586. https://doi.org/10.1002/pbc.24851

Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. / Harker-Murray, Paul D.; Drachtman, Richard A.; Hodgson, David C.; Chauvenet, Allen Russell; Kelly, Kara M.; Cole, Peter David.

In: Pediatric Blood and Cancer, Vol. 61, No. 4, 04.2014, p. 579-586.

Research output: Contribution to journalArticle

Harker-Murray, PD, Drachtman, RA, Hodgson, DC, Chauvenet, AR, Kelly, KM & Cole, PD 2014, 'Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma', Pediatric Blood and Cancer, vol. 61, no. 4, pp. 579-586. https://doi.org/10.1002/pbc.24851
Harker-Murray PD, Drachtman RA, Hodgson DC, Chauvenet AR, Kelly KM, Cole PD. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatric Blood and Cancer. 2014 Apr;61(4):579-586. https://doi.org/10.1002/pbc.24851
Harker-Murray, Paul D. ; Drachtman, Richard A. ; Hodgson, David C. ; Chauvenet, Allen Russell ; Kelly, Kara M. ; Cole, Peter David. / Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 4. pp. 579-586.
@article{44449037db2748098f76c2f5540fa81f,
title = "Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma",
abstract = "Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90{\%}. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk-stratified, response-based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579-586.",
keywords = "Chemotherapy, Hematopoietic cell transplant, Hodgkin lymphoma, Pediatric oncology, Relapse",
author = "Harker-Murray, {Paul D.} and Drachtman, {Richard A.} and Hodgson, {David C.} and Chauvenet, {Allen Russell} and Kelly, {Kara M.} and Cole, {Peter David}",
year = "2014",
month = "4",
doi = "10.1002/pbc.24851",
language = "English (US)",
volume = "61",
pages = "579--586",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma

AU - Harker-Murray, Paul D.

AU - Drachtman, Richard A.

AU - Hodgson, David C.

AU - Chauvenet, Allen Russell

AU - Kelly, Kara M.

AU - Cole, Peter David

PY - 2014/4

Y1 - 2014/4

N2 - Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk-stratified, response-based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579-586.

AB - Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk-stratified, response-based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579-586.

KW - Chemotherapy

KW - Hematopoietic cell transplant

KW - Hodgkin lymphoma

KW - Pediatric oncology

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84893463251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893463251&partnerID=8YFLogxK

U2 - 10.1002/pbc.24851

DO - 10.1002/pbc.24851

M3 - Article

C2 - 24504790

AN - SCOPUS:84893463251

VL - 61

SP - 579

EP - 586

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -